<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 10 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page9.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=10">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 10 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 10</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=10"><img src="../thumb/10.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Drugs in Sport                          2020-04 / 7a

        •  Reproterol;               Except:                       Stimulants include:
        •  Salbutamol;               •  Drospirenone; pamabrom; and ophthalmic use of  A.  Non Specified Stimulants
        •  Salmeterol;                  carbonic anhydrase inhibitors (e.g. dorzolamide,  •  adrafinil
        •  Terbutaline;                 brinzolamide).             •  amfepramone
        •  Tretoquinol (trimetoquinol);  •  Local administration of felypressin in dental  •  amiphenazole
        •  Tulobuterol;                 anaesthesia.               •  amphetamine
        •  Vilanterol.               The detection in an Athlete’s Sample at all times  •  amphetaminil
        Except:                      or In-Competition, as applicable, of any quantity  •  amiphenazole
        •  Inhaled salbutamol: maximum 1600 micrograms   of the following substances subject to threshold  •  benfluorex
          over 24 hours in divided doses, not to exceed 800   limits: formoterol, salbutamol, cathine, ephedrine,  •  benzylpiperazine
          micrograms over 12 hours starting from any dose;  methylephedrine and pseudoephedrine, in conjunction  •  bromantan
        •  Inhaled formoterol: maximum delivered dose of   with a diuretic or masking agent, will be considered  •  clobenzorex
          54 micrograms over 24 hours;  as an Adverse Analytical Finding unless the Athlete  •  cocaine
        •  Inhaled salmeterol: maximum 200 micrograms              •  cropropamide
          over 24 hours              has an approved TUE for that substance in addition   •  crotetamide
        The presence in urine of salbutamol in excess of   to the one granted for the diuretic or masking agent.  •  fencamine
        1000 ng/mL or formoterol in excess of 40 ng/mL is not   PROHIBITED METHODS  •  fenetylline
        consistent with therapeutic use of the substance and       •  fenfluramine
        will be considered as an Adverse Analytical Finding   M1 MANIPULATION OF BLOOD AND BLOOD  •  fenproporex
        (AAF) unless the Athlete proves, through a controlled   COMPONENTS  •  fonturacetam
        pharmacokinetic study, that the abnormal result was   The following are prohibited  •  furfenorex
        the consequence of the use of the therapeutic inhaled   1.  The administratuion or re-introduction of any  •  lisdexamfetamine
        dose up to the maximum indicated above.  quantity of autologous, allogenic (homologous)  •  mefenorex
        S4  HORMONE AND METABOLIC       or heterologous blood or red blood cell products  •  mephentermine
          MODULATORS                    of any origin into the circulatory system.  •  mesocarb
        The following hormone and metabolic modulators  2.  Artificially enhancing the uptake, transport or   •  methamphetamine (d-)
        are prohibited:                 delivery of oxygen, including but not limited to   •  p-methylamfetamine
        1.  Aromatase inhibitors including but not limited   perfluorochemicals, efaproxiral (RSR13) and modi-  •  modafinil
          to: 2-Androstenol; 2-Androstenone; 3-Andros-  fied haemoglobin products (e.g. haemoglobin-  •  norfenfluramine
          tenol; 3-Androstenone; 4-Androstene-3,6,17   based blood substitutes, microencapsulated   •  phendimetrazine
          trione (6-oxo), aminogluthe timide, anastrozole,   haemoglobin products) excluding supplemental   •  phentermine
          androstatrienedione, arimistane, exemestane,   oxygen by inhalation.  •  prenylamine
          formestane, letrozole, testolactone, etc.  3.  Any form of intravascular manipulation of the blood   •  prolintane
        2.  Selective estrogen receptor modulators includ-  or blood components by physical or chemical means.     A simulant not expressly listed in this section is
          ing but not limited to: (SERMs) e.g. raloxifene,           a Specified Substance
          tamoxifen, toremifene, etc.  M2 CHEMICAL AND PHYSICAL    B.  Specified Stimulants.
        3.  Other anti-estrogenic substances including but not   MANIPULATION  Including, but not limited to:
          limited to: e.g. clomiphene, cyclofenil, fulvestrant.  The following are prohibited
                                                                   •  3-methylhexan-2-amine
        4.  Agents preventing activin receptor IIB activation   1.  Tampering, or attempting to tamper, to alter the  •  4-methylpentan-2-amine
          including, but not limited to: Activin A-neutralising   integrity and validity of Samples collected during  •  4-methylhexan-2-amine (methylhexaneamine)
          antibodies; Activin receptor IIB competitors such   Doping Control. These include but are not limited to  •  5-methylhexan-2-amine
          as: Decoy activin receptors (e.g. ACE-031); Anti-
          activin receptor IIB antibodies (e.g. bimagrumab);   urine substitution and/or adulteration e.g. proteases.  •  benzfetamine
          myostatin inhibitors such as: Agents reducing or   2.  Intravenous infusions and/or injections of more  •  cathine**
          ablating myostatin expression; Myostatin-binding   than a total of 100 mL per 12 hour period except  •  cathinone and its analogues, e.g. e.g. mephedrone,
          proteins (e.g. follistatin, myostatin propeptide);   for those legitimately received in the course of   methedrone, and a-pyrrolidinovalerophenone
          Myostatin-neutralising antibodies (e.g. doma-  hospital treatments, surgical procedures or clini-  •  dimetamfetamine
          grozumab, landogrozumab, stamulumab).  cal diagnostic investigations.  •  ephedrine****
        5.  Metabolic modulators:    M3 GENE AND CELL DOPING       •  epinephrine*** (adrenaline)
          5.1  Activators of the AMP-activated protein             •  etamivan
             kinase (AMPK), e.g. AICAR, SR9009; and Per-  The following, with the potential to enhance sport  •  etilamfetamine
             oxisome Proliferator Activated Receptor δ   perfor  mance, are prohibited:  •  etilefrine
             (PPARδ) agonists e.g. 2-(2-methyl-4-((4-methyl-  1.  The use of polymers of nucleic acids or nucleic  •  famprofazone
             2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methyl-  acid analogues.  •  fenbutrazate
             thio)phenoxy) acetic acid (GW1516, GW501516);  2.  The use of gene editing agents designed to alter  •  fencamfamin
          5.2  Insulins and insulin-mimetics.  genome sequences and/or the transcriptional  •  heptaminol
          5.3  Meldonium.               post-transcriptional or epigenetic regulation of  •  hydroxyamfetamine (parahydroamphetamine)
          5.4  Trimetazidine.           gene expression.           •  isometheptene
                                     3.  The use of normal or genetically modified cells.  •  levmetamfetamine
        S5  DIURETICS AND MASKING AGENTS                           •  meclofenoxatemethylenedioxymethamphetamine
        The following diuretics and masking agents are
        prohibited, as are other substances with a similar   Substances and methods   *   Bupropion, caffeine, nicotine, phenylephrine,
        chemical structure or similar biological effect(s).  prohibited in competition  phenylpropanolamine, pipradrol and synephrine: These
        Including but not limited to:                                 substances are included in the 2018 Monitoring Programme,
        •  Desmopressin, probenecid; plasma expan-  In addition to the classes S0 to S5 and M1 to M3   and are not considered Prohibited Substances.
          ders, e.g. intravenous administration of albumin,   defined above, the following classes are prohibited   **   Cathine: Prohibited when its concentration in urine is
                                                                      greater tha 5 micrograms per millilitre.
          dextran, hydroxyethyl starch and mannitol.  in competition.  ***   Ephedrine and methylephedrine: Prohibited whenthe
        •  Acetazolamide; amiloride; bumetanide;                      concentration of either in urine is greater that 10
          canrenone; chlortalidone; etacrynic acid;  PROHIBITED SUBSTANCES  micrograms per millilitre.
          furosemide; inda  pamide; metolazone; spirono-           ****   Epinephrine (adrenaline): Not prohibited in local
          lactone; thiazides, e.g. bendroflumethiazide,  S6  STIMULANTS  administration, e.g. nasal, ophthalmologic or
                                                                      coadministration with local anaesthetic agents.
          chlorothiazide and hydro chlorothiazide; triamterene  All stimulants (including all optical isomers (e.g. d- and   *****  Pseudoephedrine: Prohibited when its concentration in
          and vaptans, e.g. tol vaptan.  l-) where relevant) are prohibited.  urine is greater that 150 micrograms per millilitre.
                          MIMS subscription call centre office hours are from
                                      Monday to Friday 08:00-16:00
                     Please feel free to contact: Riëtte (011) 280-5856; Sean (011) 280-5533</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page9.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page5.html">5</a>&nbsp;&nbsp;&nbsp;<a href="page6.html">6</a>&nbsp;&nbsp;&nbsp;<a href="page7.html">7</a>&nbsp;&nbsp;&nbsp;<a href="page8.html">8</a>&nbsp;&nbsp;&nbsp;<a href="page9.html">9</a>&nbsp;&nbsp;&nbsp;<a href="page10.html">10</a>&nbsp;&nbsp;&nbsp;<a href="page11.html">11</a>&nbsp;&nbsp;&nbsp;<a href="page12.html">12</a>&nbsp;&nbsp;&nbsp;<a href="page13.html">13</a>&nbsp;&nbsp;&nbsp;<a href="page14.html">14</a>&nbsp;&nbsp;&nbsp;<a href="page15.html">15</a>
             </td>
             <td width="35%"><a href="page11.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page11.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
